All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?

During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What do the PANTHER trial results tell us about first-line treatment for high-risk myelodysplastic syndromes (MDS)?

What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?

In this video, Sekeres discusses the randomized phase III PANTHER trial (NCT03268954), which investigated pevonedistat + azacitidine versus single-agent azacitidine as first-line treatment for patients with higher risk MDS, chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML).